Ratings by Dawson James (Jason H. Kolbert)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/28/2024 | Tonix Pharma | TNXP | New Coverage | Buy (N/A) |
0.37 (13.45) |
3535.14% | Details | |
| 7/21/2022 | ProPhase Labs, Inc | PRPH | Downgrade | Sell (Neutral) |
13.72 (0.36) |
-97.38% | Details | |
| 5/16/2022 | Kintara Therapeutics, Inc | KTRA | Downgrade | Neutral (Buy) |
0.19 (0.22) |
15.79% | Details | |
| 5/16/2022 | Kintara Therapeutics, Inc | KTRA | Downgrade | Neutral (Buy) |
0.19 (0.19) |
0% | Details | |
| 4/12/2022 | Kintara Therapeutics, Inc | KTRA | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2022 | Kintara Therapeutics, Inc | KTRA | Maintain | Buy (Buy) |
|
Details | ||
| 10/13/2021 | ProPhase Labs, Inc | PRPH | Downgrade | Neutral (Buy) |
5.42 (0.36) |
-93.36% | Details | |
| 2/1/2021 | Kintara Therapeutics, Inc | KTRA | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2021 | ProPhase Labs, Inc | PRPH | New Coverage | Buy (N/A) |
11.93 (5.42) |
-54.57% | Details |
